WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
Severe diarrhea occurred in 25% of FARYDAK treated patients. Monitor for symptoms, institute anti-diarrheal treatment...+
Novartis Oncology shares your commitment to helping patients who are living with cancer receive the medicines they need. Patient Assistance Now Oncology (PANO) offers quick and easy access to information about our wide range of resources available to your patients.
You can get information about our PANO support programs in 2 ways:
Support for Patients Includes:
The Universal Co-Pay Program offers quick and easy access to co-pay assistance for almost all Novartis Oncology products, including FARYDAK.
With the Universal Co-Pay Program, eligible*, commercially insured patients pay no more than $25 per month up to an annual maximum of $15,000 per calendar year.
Encourage your patients to find out if they're eligible for the Universal Co-Pay Program by visiting www.copay.novartisoncology.com or by calling 1-877-577-7756.
*Limitations apply. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.
FARYDAK® (panobinostat) capsules, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
IMPORTANT SAFETY INFORMATION